April 23, 2020 / 11:49 AM / a month ago

BRIEF-Merck Resubmits Supplemental Biologics License Applications For Keytruda Six-Week Dosing Schedule

April 23 (Reuters) - Merck & Co Inc:

* MERCK RESUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATIONS (SBLAS) FOR KEYTRUDA® (PEMBROLIZUMAB) SIX-WEEK DOSING SCHEDULE

* MERCK & CO INC - ADDITIONAL SBLAS FILED ACROSS ALL APPROVED ADULT INDICATIONS

* MERCK & CO INC - HAS FILED RESUBMISSIONS TO ADDRESS COMPLETE RESPONSE LETTER ISSUED IN FEBRUARY 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below